1Hochhaus A,La Rosée P.Imatinib therapy in chronic myelogenous leukemia:strategies to avoid and overcome resistance[].Leukemia.2004
2Cortes J,Kantarjian H.Newtargeted ap-proaches in chronic myeloid leukemia[].Journal of Clinical Oncology.2005
3Walz C,Sattler M.Novel targetedtherapies to overcome imatinib mesylate resistance in chronic myeloidleukemia(CML)[].Critical Reviews in Oncology Hematology.2006
4Deininger M.Resistance to imatinib:mech-anisms and management[].J Nat Compr Canc Netw.2005
5Burgess MR,Skaggs BJ,Shah NP,et al.Comparative analysis of two clinically active BCR-ABLkinase inhibitors reveals the role of conformation-specific binding in resis-tance[].Proceedings of the National Academy of Sciences of the United States of America.2005
6Cowan-Jacob SW,Guez V,Fendrich G,et al.Imatinib(STI571)resistance in chronic myelogenous leukemia:molecular basis of the underlying mechanisms and po-tential strategies for treatment[].Mini Reviews in Medicinal Chemistry.2004
7Dai Y,Rahmani M,Corey SJ,et al.A Bcr/Abl-independent,Lyn-dependent formof imatinib mesylate(STI-571)resis-tance is associated with altered expression of Bcl-2[].Journal of Biological Chemistry.2004
8Nowicki MO,Falinski R,Koptyra M,et al.BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks[].Blood.2004
9Ottmann O,Martinelli G,Dombret H,et al.AphaseⅡstudy of dasatinib in ptient with chronic myeloid leukemia(CML)in lymphoid blast crisis or Pailadelphis-chro-mosome positive acute lymohoblastic leukemia(Ph+ALL)who are resistant orintolerantto imatinib:the"START-L"CA180015study[].Blood.2005
